PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
SillaJen is expanding pharmaceutical sales through its Woosung Pharmaceutical acquisition and the Shinshin co-marketing deal while advancing clinical trials for pipelines such as BAL0891, but its drug R&D segment continues to post large losses.
2025 consolidated revenue rose sharply to KRW 9.2 billion from KRW 3.9 billion a year earlier, but the operating loss remained large at KRW 25.6 billion.
The next-generation anticancer candidate BAL0891 received US FDA orphan drug designation for acute myeloid leukemia in August 2026 and was accepted for presentation at all three major global oncology conferences (ASCO, AACR, ESMO) this year.
The pharmaceutical business, built on the Woosung Pharmaceutical acquisition (2025) and the Shinshin co-marketing agreement (June 2026), generated a standalone operating profit in H1 2026, but this was outweighed by large losses in the drug R&D segment.
SillaJen's 2019 discontinuation of the Pexavec Phase 3 trial has been referenced as a case study in recent discussions around the Financial Supervisory Service's task force on improving biotech disclosure standards.
Because losses persist, the price-to-earnings ratio is not meaningful, and the price-to-book ratio sits somewhat above officially reported levels.
SillaJen began as a biotech venture centered on the oncolytic virus immunotherapy Pexavec, but restructured its strategy after the Phase 3 PHOCUS trial in liver cancer was discontinued in 2019 following a futility recommendation from the Data Monitoring Committee.
Since then, Pexavec development has shifted toward combination therapy with immune checkpoint inhibitors such as Yervoy, Opdivo, and Libtayo rather than standalone trials.
The company's new core R&D pipeline is BAL0891, licensed from Switzerland's Basilea Pharmaceutica in 2022, a first-in-class dual inhibitor targeting TTK and PLK1, two proteins involved in cancer cell division, currently in a global Phase 1 trial for solid tumors and acute myeloid leukemia at major clinical sites in the United States and South Korea.
The second pipeline, SJ-650, is a next-generation anticancer platform whose research was accepted by the gene and cell therapy journal Molecular Therapy, and manufacturing of clinical trial material is being developed in partnership with Italian CDMO ReiThera.
Separately, the company acquired and merged with infusion-solution specialist Woosung Pharmaceutical in 2025, establishing a pharmaceutical (ETC) business whose flagship product, an acetaminophen infusion solution with the only pediatric indication of its kind in Korea, has been expanding prescriptions from tertiary hospitals into local clinics.
In June 2026, SillaJen signed a co-marketing agreement of up to five years with Shinshin Pharmaceutical covering four ETC infusion products to broaden its distribution network, and it also established a wholly owned drug wholesale subsidiary, SillaJen Healthcare.
The company also runs a smaller commerce business selling health supplements and daily necessities, though its share of revenue has been shrinking.
As a result, SillaJen's business structure is in transition toward two distinct pillars: high-risk, loss-making drug development, and a more stable pharmaceutical distribution revenue base.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩2.4B | -₩6.2B | −258.7% |
| 2025Q3 | ₩2.8B | -₩6.1B | −222.0% |
| 2025Q4 | ₩2.9B | -₩8.2B | −280.2% |
| 2026Q1 | ₩2.9B | -₩5.6B | −198.1% |
| 2026Q2 | ₩2.2B | -₩6.2B | −275.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩5B | -₩24.5B | -₩24.6B | −488.2% | −31.2% | 31.0% |
| 2023 | ₩3.9B | -₩21.3B | -₩20.4B | −541.8% | −35.5% | 33.9% |
| 2024 | ₩3.9B | -₩26.8B | -₩26.5B | −681.7% | −20.1% | 13.0% |
| 2025 | ₩9.2B | -₩25.6B | -₩24.2B | −277.4% | −22.0% | 6.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Consolidated revenue jumped to KRW 9.23 billion in 2025 from KRW 3.93 billion in 2024, driven mainly by the newly consolidated pharmaceutical sales following the Woosung Pharmaceutical merger.
Despite this, the operating loss only narrowed modestly to KRW 25.6 billion in 2025 from KRW 26.8 billion in 2024, and the net loss eased slightly to KRW 24.2 billion from KRW 26.5 billion.
The operating margin improved on paper to -277.4% in 2025 from -681.7% in 2024, but this reflects a larger revenue base rather than a genuine reduction in absolute losses.
Looking at the most recent four quarters (Q3 2025 through Q2 2026), quarterly revenue hovered around KRW 2.7-2.9 billion before slipping to KRW 2.24 billion in Q2 2026, while the quarterly operating loss widened to KRW 8.16 billion in Q4 2025, narrowed to KRW 5.65 billion in Q1 2026, then widened again to KRW 6.18 billion in Q2 2026.
Net loss attributable to owners also fluctuated without a clear trend, from KRW 7.84 billion in Q4 2025 to KRW 4.91 billion in Q1 2026 and KRW 5.49 billion in Q2 2026.
On the balance sheet, owners' equity fell from KRW 78.9 billion in 2022 to KRW 57.3 billion in 2023, jumped to KRW 131.8 billion in 2024 on a rights offering, then declined again to KRW 110.1 billion in 2025, while the debt ratio improved from 31.0% in 2022 to 6.1% in 2025.
Operating cash flow has been negative for four consecutive years (from roughly -KRW 22.1 billion in 2022 to -KRW 22.5 billion in 2025), underscoring the continuous cash burn tied to drug development.
Overall, while the pharmaceutical business has begun contributing to revenue, the scale of losses in the drug R&D segment remains large enough that it has not altered the consolidated loss trajectory.
The immuno-oncology and oncolytic virus field is a competitive arena involving multiple global pharmaceutical companies and biotechs; Amgen's Imlygic (T-VEC), a landmark precedent for oncolytic virus commercialization that SillaJen once pursued, showed meaningful response-rate improvements mainly in combination settings and remained commercially confined to narrow indications.
SillaJen is competing with BAL0891 through a differentiated dual-target mechanism against TTK and PLK1, which is being positioned as an alternative to overcome resistance issues seen with single-mechanism targeted therapies.
The fact that BAL0891 is being tested across four cohorts in a Phase 1 trial for advanced solid tumors and acute myeloid leukemia at major hospitals in both the United States and South Korea reflects an unusually broad development scope for a small biotech venture.
Separately, in the broader domestic pharma and biotech industry, South Korea's Financial Supervisory Service launched a task force in April 2026 to overhaul disclosure standards for pharmaceutical and biotech companies, aiming to address structural gaps in how clinical-stage information and licensing deal terms are communicated to investors, with SillaJen's past Phase 3 discontinuation cited as a reference case of realized investor harm.
This regulatory shift is a factor that could affect disclosure practices and investor communication across clinical-stage biotechs, including SillaJen.
On the pharmaceutical distribution side, there is a broader trend of ETC infusion solution supply expanding from tertiary hospitals into local clinics, and SillaJen is responding to this trend through its partnership with Shinshin Pharmaceutical.
BAL0891 achieved a recommended Phase 2 dose (RP2D) of 160mg at ASCO in May 2026, received US FDA orphan drug designation for acute myeloid leukemia in August, and is scheduled to present Phase 1 safety and efficacy data for both monotherapy and paclitaxel combination therapy in advanced solid tumor patients as a poster at ESMO 2026 in Madrid, Spain, from October 23-27.
The orphan drug designation grants the company benefits such as US clinical trial tax credits and access to FDA advisory and expedited review support, which could aid future clinical progress.
SJ-650 is undergoing clinical trial material manufacturing process development in partnership with ReiThera, which can be interpreted as a preparatory step toward future clinical entry.
In the pharmaceutical business, the co-marketing agreement with Shinshin Pharmaceutical is expected to reflect expanded customer reach in second-half revenue, alongside strengthened distribution functions through the SillaJen Healthcare subsidiary.
As of mid-2026, standalone cash and financial instruments remained in the range of roughly KRW 60 billion, suggesting the company has some buffer to absorb near-term R&D cash burn even without additional licensing income or external financing.
The company's stated strategy of pursuing licensing-out deals as BAL0891 clinical data accumulates remains in place, though the specific timing of any such agreement has not yet been confirmed.
SillaJen has posted consolidated net losses for four consecutive years, so a price-to-earnings ratio cannot be calculated, and valuation discussion centers mainly on the price-to-book ratio.
On a self-calculated basis, the price-to-book ratio sits somewhat above the officially reported figure, reflecting that market capitalization has held up relatively firmly even as net asset value has declined.
No dividends are paid, so there is no basis for comparing dividend yield against dividend-paying peers in the sector.
Looking at multi-year results, revenue increased markedly between 2024 and 2025, but the operating loss structure has not broken out of negative territory, so it is more accurate to describe this as a phase of revenue-base expansion coexisting with continued losses rather than a clear direction toward earnings recovery.
The degree of premium in the share price relative to net assets can be seen as partly reflecting market expectations around the accumulation of clinical data and potential licensing-out for the drug pipelines (BAL0891, SJ-650), which is more event-driven in character than something confirmed by realized earnings.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
Through the Woosung Pharmaceutical merger and the Shinshin co-marketing agreement, the pharmaceutical business began generating a standalone operating profit in H1 2026.
Its flagship infusion product, the only one in Korea with a pediatric indication, is expanding its prescription base from tertiary hospitals into local clinics. Growth in this segment could partly cushion cash burn in the drug R&D business.
BAL0891 was accepted for presentation at all three major global oncology conferences (ASCO, AACR, ESMO) in 2026 and received US FDA orphan drug designation for acute myeloid leukemia in August.
This can be interpreted as a degree of external validation of the candidate's medical importance and potential at an early clinical stage. SJ-650 also received technical validation through acceptance of its research in the international journal Molecular Therapy.
The debt ratio fell from 31.0% in 2022 to 6.1% in 2025, and standalone cash and financial instruments stood at roughly KRW 60 billion at the end of H1 2026.
This suggests a buffer to sustain R&D spending for some period without additional fundraising, as proceeds from a past large-scale rights offering have not yet been fully depleted.
Consolidated operating and net losses have exceeded KRW 20 billion annually every year from 2022 to 2025, and even in 2025, when revenue grew, the operating margin was still -277.4%.
Over the most recent four quarters, quarterly operating losses have fluctuated between roughly KRW 5.6 billion and KRW 8.2 billion without a clear improving trend. Profit contribution from the pharmaceutical business alone is insufficient to offset losses in the drug R&D segment.
Both BAL0891 and SJ-650 remain at the Phase 1 stage or earlier, requiring substantial time and additional funding before commercialization or licensing-out could occur.
The 2019 discontinuation of the Pexavec Phase 3 trial following a futility assessment stands as a prominent precedent for how clinical development risk has previously materialized at SillaJen.
Response signals observed in early trials are based on small patient cohorts and may not necessarily be reproduced in later-stage trials.
Operating cash flow has been negative every year from 2022 through 2025, reflecting an ongoing structural cash burn tied to drug development. The company carried out a rights offering of roughly KRW 103.2 billion in 2024, followed by an additional third-party placement related to the Woosung Pharmaceutical acquisition.
If external cash inflows such as licensing-out deals are delayed, the need for further fundraising could resurface.
In the ASCO 2026 data for BAL0891, efficacy signals were observed in only eight patients at the 120mg-and-above dose cohort, meaning the evidence base remains small.
While the maximum tolerated dose and recommended Phase 2 dose have been established, there remains a possibility that response rates may not be reproduced in later dose-expansion or Phase 2 stages. The prior discontinuation of the Pexavec Phase 3 trial illustrates how risk can materialize at later clinical stages.
In April 2026, South Korea's Financial Supervisory Service launched a task force to overhaul pharmaceutical and biotech disclosure standards, citing SillaJen's history as a reference case of realized investor harm.
If the resulting disclosure framework is finalized, the way clinical progress and licensing deal terms are disclosed could become more stringent. This is an industry-wide regulatory shift but one that could directly affect SillaJen going forward.
The immuno-oncology and oncolytic virus field involves competition from numerous global pharmaceutical companies and biotechs, and the earlier oncolytic virus commercialization precedent, Imlygic, showed meaningful effects mainly in narrow-indication combination settings.
Whether BAL0891's dual-target mechanism will be recognized as commercially differentiated depends on subsequent clinical data and the competitive drug landscape. The possibility that licensing-out negotiations could be delayed or fall short of expectations cannot be ruled out.
At ESMO 2026 in Madrid, Spain, Phase 1 safety and efficacy data for BAL0891 monotherapy and paclitaxel combination therapy will be presented as a poster. It will be worth checking whether the signals seen at ASCO 2026 hold up in expanded cohorts.
Q3 2026 results should be checked for the trend in revenue and profit contribution from the pharmaceutical segment versus the scale of losses in the drug R&D segment. Whether the Shinshin co-marketing effect is fully reflected is also worth watching.
This is a period to check the progress of BAL0891's Phase 1 dose-expansion cohorts, how the orphan drug designation benefits are being utilized in development, and whether licensing-out discussions are advancing.
Tracking the trend in standalone cash and financial instrument balances will help assess whether additional financing may become necessary. Monitoring the pace of R&D spending and the timing of remaining cash depletion is warranted.
SillaJen substantially grew consolidated revenue in 2025 by securing a more stable pharmaceutical revenue base through the Woosung Pharmaceutical acquisition and merger, but large losses in the drug R&D segment have persisted for four consecutive years, meaning the consolidated loss trend itself has not been reversed.
BAL0891 has accumulated academic and regulatory validation in 2026, including acceptance for presentation at all three major global oncology conferences and US FDA orphan drug designation, but since this is still early clinical data based on small patient cohorts, considerable time and further data will be needed before commercialization or licensing-out.
Financially, the debt ratio has fallen sharply and standalone cash reserves remain at a certain level, which relatively lowers near-term liquidity concerns, though the persistent annual outflow in operating cash flow points to structural cash-burn pressure.
The company's history of discontinuing the Pexavec Phase 3 trial has been cited as a reference case in recent discussions around improving biotech disclosure standards at the Financial Supervisory Service, suggesting scrutiny of its information disclosure and investor communication practices is likely to continue.
Ultimately, assessing SillaJen requires watching both the pace at which the pharmaceutical business's revenue contribution expands and the progress of clinical data accumulation and licensing-out for BAL0891 and SJ-650, with both tracks still in progress rather than settled outcomes.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.